FindTrial
Sign In

Treatment of Generalized Anxiety Disorder by Ood saleeb

Therapeutic Evaluation of Ood saleeb (Paeonia officinalis) in the Management of Izterab-e-Nafsani (Generalized Anxiety Disorder) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/055988
Enrollment
60
Registered
2023-08-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F411- Generalized anxiety disorder

Interventions

Intervention1: Powder of Ood saleeb (Paeonia officinalis): 4 Capsules (500mg each), Orally will be given after meals with water for 2 months Control Intervention1: Placebo (Wheat flour Capsules): 4 C

Sponsors

Department of Moalejat, Ajmal Khan Tibbiya College, Aligarh Muslim University, Aligarh,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patients fulfilling the criteria of diagnostic and statistical manual of mental disorder 5th edition (DSM-V) for the diagnosis of Generalized Anxiety Disorder (GAD) and having mild to moderate anxiety as per Hamiltonâ??s anxiety rating scale (HAM-A) were selected. 1.Patients of either gender. 2.Patients between age of 18-60years. 3.Patients presenting with symptoms of anxiety disorders. 4.On the basis of Hamilton Anxiety Rating Scale patients having mild to moderate anxiety (HARS up-to 25)

Exclusion criteria

Exclusion criteria: 1.Patients below 18 and more than 60 years. 2.Subject having anxiety with co-morbid somatic/psychiatric disorders(e.g. mixed anxiety with depression). 3.Patient with any cardiac and respiratory disease or any other medical condition that may have prejudiced the diagnosis or rating of anxiety. 4.Suspected case of hyperthyroidism. 5.Any chronic debilitating disease. 6.Severe anxious patients. 7.Patient taking any medicine reported to cause anxiety 8.Pregnant and lactating women. 9.Patient who fails to give consent. 10.Patient who fails to follow up.

Design outcomes

Primary

MeasureTime frame
Improvement in Objective parameters The outcomes measures were recorded by using Hamiltonâ??s anxiety scale (HARS) For the 14 items the values on scale ranges from zero to four, zero-no anxiety, one-mild, two-moderate, three-severe, four-very severe. 1.12 â?? mild 2.18-25- mild to moderate 3.26-30-moderate to severe Timepoint: 2 months on baseline & after completion—

Secondary

MeasureTime frame
Improvement in Subjective parameters: Restlessness Irritability Palpitations Insomnia Feeling of fatigue Timepoint: 2 months on Fortnightly follow ups—

Countries

India

Contacts

Public ContactDr Swaleha Akhtar

Ajmal Khan Tibbiya College, Aligarh Muslim University

tanzeel1967@gmail.com9448123337

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026